Want to see TSE:PRN full AI Analyst Report?

Profound Medical (PRN) Price & Analysis

106 Followers

PRN Stock Chart & Stats

C$10.28

C$0.06(0.58%)

At close: Jul 27 4:00 PM EDT

C$10.28

C$0.06(0.58%)

Day’s Range― - ―

52-Week RangeC$5.23 - C$12.40

Previous CloseN/A

Volume2.48K

Average Volume (3M)24.45K

Market Cap

C$355.10M

Enterprise ValueC$298.96

Total Cash (Recent Filing)C$38.21M

Total Debt (Recent Filing)C$7.37M

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Oct 29, 2026

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding36,532,593

10 Day Avg. Volume21,380

30 Day Avg. Volume24,453

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)3.58

Price to Sales (P/S)14.48

P/FCF Ratio-6.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$15.35

Price Target Upside49.30% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.84

Revenue Forecast (FY)C$26.12M

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth & High Gross MarginsSustained double‑digit revenue acceleration and durable ~70%+ gross margins indicate scalable unit economics for TULSA‑PRO. High margins provide structural leverage as installs and procedure volume grow, enabling future operating‑leverage gains if commercial adoption continues.

Compelling Clinical Differentiation (CAPTAIN)Randomized evidence showing superior quality‑of‑life and safety creates durable clinical differentiation versus radical prostatectomy. Strong outcomes drive clinician preference, payer support, and sustained procedure adoption, underpinning long‑term demand for the imaging‑guided TULSA platform.

Growing Installed Base, Pipeline & Reimbursement TailwindsAn expanding install base and a sizable qualified pipeline provide structural revenue runway from capital sales plus recurring disposables. Concurrent payer coverage expansion and proposed higher hospital payments improve procedure economics, supporting durable commercial uptake and site‑level ROI.

Bears Say

High And Worsening Cash BurnPersistent negative operating and free cash flow at material levels creates ongoing funding needs and dilutive financing risk. Even with revenue momentum, sustained cash burn pressures the balance sheet and constrains the company’s ability to invest opportunistically without external capital.

Deep Net Losses And Profitability GapVery negative net margins show operating costs still far exceed current revenue, limiting self‑funding capacity. This structural profitability gap prolongs reliance on external financing and increases execution risk if revenue conversion or margin improvements stall.

Installation/Logistics Delays & Revenue Timing RiskProlonged install and logistics lead times create timing variability in revenue recognition and slow conversion of booked orders into procedures. Operational bottlenecks and site transitions can delay consumable recurring revenue, undermining near‑term cash flow predictability and pipeline conversion rates.

Profound Medical News

Profound Medical upgraded to Strong Buy from Outperform at Raymond James

Raymond James upgraded Profound Medical (PROF) to Strong Buy from Outperform with an unchanged price target of $11....

19d ago

PROF

Profound Medical upgraded to Strong Buy at Raymond James after positive data

As previously reported, Raymond James analyst Michael Freeman upgraded Profound Medical (PROF) to Strong Buy from Outperform with...

19d ago

PROF

Profound Medical Launches Global Prostate Patient Advocacy Community

Profound Medical ( ($TSE:PRN) ) has issued an update. On August 13, 2026, Profound Medical launched Let’s Huddle,...

1d ago

PROF

Analyst Reaffirms Buy on TULSA Maker as Deferred Shipments, Record Orders and Strong 2H Outlook Signal Robust Underlying Growth

Raymond James analyst Michael W. Freeman has maintained their bullish stance on PRN stock, giving a Buy rating...

5d ago

PROF

Profound Medical Boosts Orders, Narrows Loss as TULSA Adoption and Coverage Expand

An update from Profound Medical ( ($TSE:PRN) ) is now available. Profound Medical reported second-quarter 2026 results marked...

8d ago

PROF

Profound Medical Highlights New TULSA Quality-of-Life Data

Profound Medical ( ($TSE:PRN) ) has provided an update. On July 24, 2026, Profound Medical reported new data...

22d ago

PROF

Source Rock Royalties Declares Monthly Dividend and Issues Incentive RSUs

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Source Rock Royalties Ltd. declared a monthly cash dividend...

30d ago

PROF

Profound Medical Shareholders Back Board, Question Incentive Plan

An announcement from Profound Medical ( ($TSE:PRN) ) is now available. At its Annual General and Special Meeting...

3M ago

PROF

Telix announces LoI to collaborate with EDAP TMS and Profound Medical

Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with...

3M ago

EDAP

PROF

Profound Medical Highlights TULSA Advances at AUA 2026

Profound Medical ( ($TSE:PRN) ) has provided an update. On May 14, 2026, Profound Medical announced that its...

3M ago

PROF

Profound Medical files to sell 921,428 common shares for holders

17:07 EDT Profound Medical (PROF) files to sell 921,428 common shares for holders Published first on TheFly –...

3M ago

PROF

Profound Medical price target lowered to $10 from $12 at Stifel

Stifel analyst Rick Wise lowered the firm’s price target on Profound Medical (PROF) to $10 from $12 and...

3M ago

PROF

Profound Medical Schedules First-Quarter 2026 Earnings Release

Profound Medical ( ($TSE:PRN) ) has issued an update. Profound Medical Corp., a commercial-stage medical device maker, develops...

4M ago

PROF

Profound Medical to Present Business Update at Conference

Profound Medical ( ($TSE:PRN) ) just unveiled an update. On April 14, 2026, Profound Medical Corp. announced that...

4M ago

PROF

PRN FAQ

What was Profound Medical’s price range in the past 12 months?

Profound Medical lowest stock price was C$5.23 and its highest was C$12.40 in the past 12 months.

What is Profound Medical’s market cap?

Profound Medical’s market cap is C$355.10M.

When is Profound Medical’s upcoming earnings report date?

Profound Medical’s upcoming earnings report date is Oct 29, 2026 which is in 75 days.

How were Profound Medical’s earnings last quarter?

Profound Medical released its earnings results on Aug 06, 2026. The company reported -C$0.362 earnings per share for the quarter, missing the consensus estimate of -C$0.337 by -C$0.025.

Is Profound Medical overvalued?

According to Wall Street analysts Profound Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Profound Medical pay dividends?

Profound Medical does not currently pay dividends.

What is Profound Medical’s EPS estimate?

Profound Medical’s EPS estimate is -0.32.

How many shares outstanding does Profound Medical have?

Profound Medical has 36,532,593 shares outstanding.

What happened to Profound Medical’s price movement after its last earnings report?

Profound Medical reported an EPS of -C$0.362 in its last earnings report, missing expectations of -C$0.337. Following the earnings report the stock price went down -7.207%.

Which hedge fund is a major shareholder of Profound Medical?

Currently, no hedge funds are holding shares in TSE:PRN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Profound Medical Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

17.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Profound Medical

Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.

Profound Medical (PRN) Earnings & Revenues

Historic Earnings Reports

PRN Stock 12 Month Forecast

Average Price Target

C$15.35

▲(49.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"C$5","8":"C$8","11":"C$11","14":"C$14","17":"C$17"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.74324372,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$16.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.34797341,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$15.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.9527031,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$13.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8,11,14,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.38,10.869480286153847,11.358960572307693,11.848440858461538,12.337921144615384,12.82740143076923,13.316881716923078,13.806362003076924,14.29584228923077,14.785322575384615,15.274802861538461,15.764283147692307,16.253763433846153,{"y":16.74324372,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.38,10.762151800769232,11.144303601538462,11.526455402307693,11.908607203076924,12.290759003846155,12.672910804615384,13.055062605384617,13.437214406153846,13.819366206923078,14.201518007692307,14.58366980846154,14.965821609230769,{"y":15.34797341,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.38,10.654823315384617,10.929646630769232,11.204469946153846,11.479293261538462,11.754116576923078,12.028939892307694,12.30376320769231,12.578586523076924,12.85340983846154,13.128233153846155,13.40305646923077,13.677879784615385,{"y":13.9527031,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.77,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >